Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Up 179.6% in February

Synaptogenix, Inc. (NASDAQ:SNPXGet Free Report) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 479,500 shares, a growth of 179.6% from the January 31st total of 171,500 shares. Based on an average trading volume of 742,300 shares, the days-to-cover ratio is presently 0.6 days. Approximately 2.4% of the shares of the company are sold short.

Synaptogenix Stock Down 4.7 %

Shares of NASDAQ SNPX traded down $0.01 during midday trading on Thursday, hitting $0.21. 325,239 shares of the company’s stock were exchanged, compared to its average volume of 993,464. Synaptogenix has a 12 month low of $0.14 and a 12 month high of $1.88. The company’s 50 day moving average price is $0.22 and its 200 day moving average price is $0.31. The firm has a market capitalization of $4.21 million, a PE ratio of -0.21 and a beta of 1.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in Synaptogenix by 248.9% in the 1st quarter. Vanguard Group Inc. now owns 216,836 shares of the company’s stock valued at $1,678,000 after acquiring an additional 154,688 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Synaptogenix during the 2nd quarter worth $83,000. Finally, Prelude Capital Management LLC raised its holdings in shares of Synaptogenix by 13.9% during the 2nd quarter. Prelude Capital Management LLC now owns 14,364 shares of the company’s stock worth $75,000 after buying an additional 1,750 shares in the last quarter. 2.79% of the stock is currently owned by institutional investors.

Synaptogenix Company Profile

(Get Free Report)

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.

Further Reading

Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with's FREE daily email newsletter.